Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer
IRCT20140818018842N34Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2023
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in triple-negative breast cancer (TNBC), sponsored by Tehran University of Medical Sciences. Primary endpoints: Number of patients with grade 3-5 TIL infusion-related adverse events and Objective response rate. Started May 2023; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on IRCT20140818018842N34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N34.